TrialEuropean journal of heart failure2022

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.

Kirsty McDowell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.